The post of director of business management is a new position within Cancer Research Technology, demanded in part by ambitious future plans
Cancer Research Technology (CRT) announces the appointment of Phil L'Huillier as director of business management.
Previously, he was director of global licensing and business development at BioFocus Discovery, a UK listed drug discovery company.
Prior to BioFocus, he headed ProBio, a US specialty IP commercialisation company, involved in international licensing and partnering in the pharmaceutical, genomics and agbiotech sectors (now part of the Pharming group).
The post of director of business management is a new position within CRT, demanded in part by CRT's ambitious future plans.
These include the expansion of its oncology focused development laboratory enabling CRT to take early-stage projects further downstream, and growing the development services within Europe as well as entry into the USA.
Keith Blundy, CRT's chief operating officer, stated: "We are delighted to welcome Phil to CRT.
"CRT's business management team and indeed the organisation as a whole will benefit greatly from his guidance and expertise".
Cancer Research Technology is an oncology focused technology transfer and development company, which aims to maximise cancer patient benefit.
CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners.
CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies.
CRT is wholly owned by Cancer Research UK, which claims to be the largest independent funder of cancer research in the world.
